COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026
The latest adjustable lumbar support from FEATOL combines stability with comfort, providing much-needed mobility support for those experiencing lower back fatigue NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- With more [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) ( [...]
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
30/06/2026
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity [...]
Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners
30/06/2026
Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing Intravacc offers four complementary vaccine [...]
Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
30/06/2026
Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the Salipro® platform STOCKHOLM, June 30, 2026 (GLOBE NEWSWIRE) -- Salipro Biotech AB today announced the [...]
Transactions in connection with share buy-back program
30/06/2026
Company announcement no. 23 - 26 30 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
smartbax secures additional financing to advance lead antibiotic program to IND filing
30/06/2026
Munich, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful second closing of its Pre- [...]
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
30/06/2026
Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/06/2026
This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration Under the terms of the agreement, Nxera is eligible [...]
HUTCHMED to Announce 2026 Half-Year Financial Results
30/06/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
30/06/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
30/06/2026
ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma (“Orion”) and Shilpa Biologicals Private Limited [...]
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026
Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
Le Centre National de Protonthérapie du Portugal sera équipé de deux solutions Proteus®ONE d’IBA
30/06/2026
Louvain-la-Neuve, Belgique, le 30 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
30/06/2026
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve [...]

Pages